Mirxes Holding Company Limited (HKG:2629)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
30.00
+0.50 (1.69%)
At close: May 28, 2025, 4:00 PM HKT
Market Cap 7.89B
Revenue (ttm) 157.55M
Net Income (ttm) -717.15M
Shares Out 263.14M
EPS (ttm) -5.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,659,700
Average Volume 4,120,010
Open 29.50
Previous Close 29.50
Day's Range 29.25 - 30.30
52-Week Range 29.00 - 31.05
Beta n/a
RSI n/a
Earnings Date n/a

About Mirxes Holding Company

Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related ... [Read more]

Industry Laboratory Apparatus and Furniture
Founded 2014
Employees 352
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2629
Full Company Profile

Financial Performance

In 2024, Mirxes Holding Company's revenue was $20.28 million, a decrease of -16.14% compared to the previous year's $24.19 million. Losses were -$92.33 million, 33.4% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.